Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
AstraZeneca PLC
AZN
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $285.1B
$194.32
▲ +5.69%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$137.22 - $212.71
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 27.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Diversified portfolio of blockbuster drugs with strong market positions and patent protection
- Global distribution network and established relationships with primary and specialty care physicians
- Strategic AI-driven partnerships accelerating drug discovery and reducing time-to-market
- Significant R&D capabilities and pipeline depth across high-unmet-need therapeutic areas
- Strong financial position enabling continued investment in innovation and M&A opportunities
Bear Case
2 risks
- Low volatility (beta 0.2).
- High premium - requires strong execution
Growth
Stable outlook
Expanding oncology pipeline with innovative targeted therapies addressing high-unmet medical needs
Value
High premium - requires strong execution
Momentum
Weak
-9.7% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
Modest
1.70% yield
Smart-money signal
Who's buying AZN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 27, 2026
APR 29, 2026
Reported EPS of $2.58 vs $2.52 consensus (+2.4% surprise). Revenue of $15.3B vs $14.9B expected (+2.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+2.4%
Next: Apr 27, 2026
Revenue trend · last 8Q
—
—
+24%
+7%
+12%
+12%
+4%
+13%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$12.9B
$13.6B
$14.9B
$13.6B
$14.5B
$15.2B
$15.5B
$15.3B
Margins · last 8Q
Gross
82.5%
Operating
27.8%
Profit
20.1%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
No analyst coverage on file for this stock yet.